Overview

Location [1]
12p13.33
Protein [2]
ELKS/Rab6-interacting/CAST family member 1
Synonyms [1]
ELKS, RAB6IP2, Cast2, ERC-1

ERC1 is altered in 0.08% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, dedifferentiated liposarcoma, and squamous cell carcinoma of unknown primary having the greatest prevalence of alterations [3].

ERC1 GENIE Cases - Top Diseases

The most common alterations in ERC1 are ERC1-ROS1 Fusion (0.10%), ERC1-RET Fusion (0.04%), ERC1-RAD52 Fusion (0.02%), ERC1-CCND2 Fusion (0.04%), and ERC1-KDM5A Fusion (0.04%) [3].

ERC1 GENIE Cases - Top Alterations

Significance of ERC1 in Diseases

Thyroid Gland Papillary Carcinoma +

Malignant Solid Tumor +

Histiocytosis +

Lymphoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Thyroid Gland Medullary Carcinoma +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.